{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Telangiectasis&page=5",
    "query": {
      "condition": "Telangiectasis",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 98,
    "total_pages": 10,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Telangiectasis&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Telangiectasis&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T07:21:19.232Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02287558",
      "title": "Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hereditary Hemorrhagic Telangiectasia",
        "Idiopathic Vascular Ectasia"
      ],
      "interventions": [
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2015-01-27",
      "completion_date": "2019-06-01",
      "has_results": false,
      "last_update_posted_date": "2020-07-15",
      "last_synced_at": "2026-10-27T07:21:19.232Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02287558"
    },
    {
      "nct_id": "NCT00457145",
      "title": "Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Telangiectasia"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Eye Institute (NEI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 5,
      "start_date": "2007-03-27",
      "completion_date": "2007-10-24",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-27T07:21:19.232Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00457145"
    },
    {
      "nct_id": "NCT01205035",
      "title": "High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Retinal Diseases",
        "Telangiectasis"
      ],
      "interventions": [
        {
          "name": "ranibizumab 2.0mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eye Center of Northern Colorado, P.C.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2010-10",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2015-04-10",
      "last_synced_at": "2026-10-27T07:21:19.232Z",
      "location_count": 1,
      "location_summary": "Fort Collins, Colorado",
      "locations": [
        {
          "city": "Fort Collins",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01205035"
    },
    {
      "nct_id": "NCT06659640",
      "title": "A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hereditary Hemorrhagic Telangiectasia"
      ],
      "interventions": [
        {
          "name": "ALN-6400",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2024-11-07",
      "completion_date": "2028-06-22",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-10-27T07:21:19.232Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Cypress, California • Gainesville, Florida + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cypress",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06659640"
    },
    {
      "nct_id": "NCT04095273",
      "title": "Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Elimusertib (BAY1895344)",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab (Keytruda®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2019-09-30",
      "completion_date": "2023-04-11",
      "has_results": false,
      "last_update_posted_date": "2024-04-02",
      "last_synced_at": "2026-10-27T07:21:19.232Z",
      "location_count": 8,
      "location_summary": "Palo Alto, California • New Haven, Connecticut • Baltimore, Maryland + 5 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04095273"
    },
    {
      "nct_id": "NCT01158807",
      "title": "Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hereditary Hemorrhagic Telangiectasia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Unity Health Toronto",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 2272,
      "start_date": "2010-04-08",
      "completion_date": "2025-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-10-27T07:21:19.232Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01158807"
    },
    {
      "nct_id": "NCT06664853",
      "title": "Open-Label Extension of EryDex Study IEDAT-04-2022",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ataxia Telangiectasia"
      ],
      "interventions": [
        {
          "name": "Dexamethasone sodium phosphate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Quince Therapeutics S.p.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2024-12-11",
      "completion_date": "2026-01-30",
      "has_results": true,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-10-27T07:21:19.232Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • New Brunswick, New Jersey + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06664853"
    },
    {
      "nct_id": "NCT00640003",
      "title": "Baclofen Treatment of Ataxia Telangiectasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Ataxia Telangiectasia"
      ],
      "interventions": [
        {
          "name": "Baclofen",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2007-04",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2017-12-20",
      "last_synced_at": "2026-10-27T07:21:19.232Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00640003"
    },
    {
      "nct_id": "NCT04887311",
      "title": "MBM-01 (Tempol) for the Treatment of Ataxia Telangiectasia",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ataxia Telangiectasia Louis-Bar",
        "Ataxia Telangiectasia in Children",
        "Ataxia Telangiectasia"
      ],
      "interventions": [
        {
          "name": "MBM-01",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Matrix Biomed, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2021-07",
      "completion_date": "2022-12",
      "has_results": false,
      "last_update_posted_date": "2021-05-17",
      "last_synced_at": "2026-10-27T07:21:19.232Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04887311"
    },
    {
      "nct_id": "NCT02000089",
      "title": "The Cancer of the Pancreas Screening-5 CAPS5)Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pancreas Cancer",
        "Peutz-Jeghers Syndrome (PJS)",
        "Gene Mutation",
        "Germline Mutation Carrier",
        "Lynch Syndrome"
      ],
      "interventions": [
        {
          "name": "Secretin",
          "type": "DRUG"
        },
        {
          "name": "MRI",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Tumor marker gene test with CA19-9",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST",
        "OTHER"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9000,
      "start_date": "2014-01-06",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-22",
      "last_synced_at": "2026-10-27T07:21:19.232Z",
      "location_count": 9,
      "location_summary": "New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02000089"
    }
  ]
}